Loading, please wait...
NOVEMBER 2018 RESIDENT SEMINAR
Please join us for the first in our Resident Seminar series on Friday, November 16, 2018 at 1:00 PM. Presented by PGY1 and PGY2 residents from within the St. Louis area, this series will focus on current therapeutic topics in the practice of pharmacy. All sessions will be held in the classrooms in the Academic & Research Building (ARB) on the third floor. For a map of the campus and directions, please click here »
|
|
ARB 304
|
ARB 305
|
ARB 336
|
ARB 354
|
ARB 355
|
|
BLOCK 1
1:00 – 1:45
|
Antistaphylococcal Penicillins or Cephalosporins for the treatment of MSSA Bacteremias
Daniel Pearson, Pharm.D.
|
Improving COPD Outcomes with Pharmacy Services in Ambulatory Care
Della Mitchell, Pharm.D.
|
Weighing the Options: Direct Oral Anticoagulant Use in Extreme Obesity
Amanda Bultas, Pharm.D.
|
Management of Heparin-Induced Thrombocytopenia: Will DOACs Be the Next Big Hit?
Emily Shor, Pharm.D.
|
An evaluation of the use of thrombolytics in wake-up stroke
Ijeoma Onyema, Pharm.D.
|
|
1:45 – 1:55 pm
|
Travel Time to accommodate movement between rooms
|
||||
|
BLOCK 2
1:55 – 2:40
|
Extended Infusion Beta-Lactams in Critically Ill Patients
Alaina DeKerlegand, Pharm.D.
|
Goal heart rate versus target beta blocker dose in chronic systolic heart failure
Paige Stipanovich, Pharm.D.
|
Revisiting the cardiovascular role of aldosterone antagonists
Darcy Holzum, Pharm.D.
|
Fixed Versus Variable Dosing of Prothrombin Complex Concentrate
Lauren Jacobsmeyer, Pharm.D.
|
Perioperative Anticoagulation Management of Warfarin for Atrial Fibrillation: To Bridge or Not to Bridge
Rob Yang, Pharm.D.
|
** Up to 0.75 hours of CE credit are available for each activity, for a maximum possible 1.50 hours if participants attend activities in both time blocks.**
REGISTRATION INFORMATION
This event has mutliple concurrent sessions. To register, please select no more than ONE session per time block below. Registration is free, but is required in advance. Due to limited space, only those participants who register before 12:00 PM on Tuesday, November 13, 2018 will be able to request parking access on campus. To request parking, pleaes indicate that you would like a space in the registration questionnaire by the deadline above. If you do not request parking on our campus, or if you do not submit your requst by the deadline, you will be re-directed upon arrival.
HANDOUTS
Paper copies of handouts will be provided in each room as well as electronically on this website. Copies of PowerPoint slides are not provided. To access the handouts electronically, participants should ensure they are logged in before accessing this event. Click the + symbol beside the session, which will expand the module. A clickable text link to download the handout as a PDF file will be present.
ATTENDANCE
All participants will be required to sign in on the paper sheets, located within each room. Paper sign-in sheets will be reconciled against electronic credit reporting on this website.
CPE CREDIT
Participants must claim all CPE credit electronically. Participants may claim no more than one 45-minute session for each time block.
SPECIAL ACCOMMODATIONS
If you require special accommodations, please notify us in advance. Every effort will be made to make accommodations where necessary.
Date: Nov 16, 2018 01:00 PM - 02:40 PM
Location: Academic & Research Building
CE Hours
7.75
Registration closes on Dec 01, 2018 12:00 AM
Activity Type
- Knowledge
Target Audience(s)
- Pharmacists
Requirements for CE Credit
In order to receive CPE Credit, participants are required to submit an evaluation for the session. Evaluations will be housed online at this web address for 14 days, after which time they will be closed.Immediately upon submission of the online evaluation, a report will be automatically generated and submitted to CPE Monitor using the NABP ePID and DOB stored in the participant's account profile. Participants should allow up to 48 hours for the credit to sync with their online NABP e-Profiles. Paper statements of credit are not provided. Only ONE session may be claimed per each time block - if multiple concurrent sessions are claimed, participants forfeit CPE credit for the activity.
Participants are responsible for ensuring accuracy of credit reporting and receipt of credit. It is recommended that participants log on and reivew the information under "my account" prior to submitting the evaluation. NABP ePID and date of birth must be accurate for credit reporting to occur. Evaluations cannot be reopened after 14 days.
Participants are encouraged to check their NABP eProfiles for receipt of credit within one week of submitting their evaluation(s). If a participant notices an error in credit on their NABP e-profile, they are encouraged to contact our office as soon as possible. To best comply with ACPE's CE credit reporting policy, St. Louis College of Pharmacy is unable, for any reason, to award or correct CE credit if more than 60 days have passed from the event.
REGISTRATION INSTRUCTIONS: Topics in concurrent time blocks are labeled as B1 and B2 to designate Blocks 1 and 2, respectively. To register, check the open box for a session for each of B1, and B2. As a reminder, you may only claim credit for one session in each time block. When you are ready, click the green "Register Now" button at the bottom of the page to register for those sessions you have checked. If you are not already logged in, you will be asked to do so.
Pharmacy Students should NOT use this page to register. Students should CLICK HERE » to register.
Registration closes on Dec 01, 2018
at 12:00 AM
Registration closes on Dec 01, 2018
at 12:00 AM
Registration Closed
Registration Closed
Note: This session is one of five concurrent sessions during Block 1.
Objectives
- Explain the cefazolin inoculum effect and its impact on treatment of patients with methicillin susceptible staphylococcus aureus bacteremia.
- Describe the current clinical evidence available for the use of ceftriaxone in the treatment of methicillin susceptible staphylococcus aureus bacteremias.
Speaker(s)/Author(s)
|
C. Daniel Pearson, Pharm.D.
|
Activity Number
0033-0000-18-088-L01-P
Date:
11/16/18
Time:
01:00 PM - 01:45 PM
CE Hours
1.00
Location
ARB 304
Registration Closed
Registration Closed
Registration Closed
Note: This session is one of five concurrent sessions during Block 1.
Objectives
- Describe the effects of COPD management strategies on disease progression.
- Identify strategies utilized to improve COPD management with pharmacy services in ambulatory care.
Speaker(s)/Author(s)
|
Della Mitchelle, Pharm.D.
|
Activity Number
0033-0000-18-097-L01-P
Date:
11/16/18
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
Location
ARB 305
Registration Closed
Registration Closed
Registration Closed
Note: This session is one of five concurrent sessions during Block 1.
Objectives
- Compare and contrast pharmacokinetic properties of drugs in obese and non-obese patients.
- Describe pertinent primary literature involving efficacy and safety of direct oral anticoagulants in extremely obese patients.
Speaker(s)/Author(s)
|
Amanda Bultas, Pharm.D.
|
Activity Number
0033-0000-18-094-L01-P
Date:
11/16/18
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
Location
ARB 336
Registration Closed
Registration Closed
Registration Closed
Note: This session is one of five concurrent sessions during Block 1.
Objectives
- Describe the appropriate steps for management of a patient with suspected heparin-induced thrombocytopenia.
- Compare and contrast currently approved agents for treatment of heparin-induced thrombocytopenia.
- Assess the recent literature evaluating the utility of direct oral anticoagulants for the treatment of heparininduced thrombocytopenia.
Speaker(s)/Author(s)
|
Emily Shor, Pharm.D.
|
Activity Number
0033-0000-18-091-L01-P
Date:
11/16/18
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
Location
ARB 354
Registration Closed
Registration Closed
Registration Closed
Note: This session is one of five concurrent sessions during Block 1.
Objectives
- Identify the eligibility criteria for receiving fibrinolytics in stroke patients.
- Recognize methods used in current primary literature to evaluate the efficacy and safety of alteplase in patients with wake-up stroke.
- Identify appropriate therapies from primary literature and current guidelines for patients with wake-up stroke.
Speaker(s)/Author(s)
|
Ijeoma E. Onyema, Pharm.D.
|
Activity Number
0033-0000-18-099-L01-P
Date:
11/16/18
Time:
01:00 PM - 01:45 PM
CE Hours
0.75
Location
ARB 355
Registration Closed
Registration Closed
Registration Closed
Note: This session is one of five concurrent sessions during Block 2.
Objectives
- Describe the pharmacokinetic and pharmacodynamic principles that pertain to beta-lactam antibiotics.
- Explain the effect of extended-infusion administration on efficacy of beta-lactam antibiotics.
- Summarize literature evaluating the clinical impact of extended-infusion administration of beta-lactam antibiotics in critically-ill patients and patients with febrile neutropenia.
Speaker(s)/Author(s)
|
Alaina DeKerlegand, Pharm.D.
|
Activity Number
0033-0000-18-098-L01-P
Date:
11/16/18
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Location
ARB 304
Registration Closed
Registration Closed
Registration Closed
Note: This session is one of five concurrent sessions during Block 2.
Objectives
- Identify the mechanisms of action of beta blockers and ivabradine.
- Explain the rationale of heart rate as a therapeutic target in heart failure.
- Evaluate the role of beta blockers and ivabradine in the treatment of chronic systolic heart failure.
Speaker(s)/Author(s)
|
Paige Stipanovich, Pharm.D.
|
Activity Number
0033-0000-18-089-L01-P
Date:
11/16/18
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Location
ARB 305
Registration Closed
Registration Closed
Registration Closed
Note: This session is one of five concurrent sessions during Block 2.
Objectives
- Describe the risks of aldosterone antagonists.
- Identify opportunities when an aldosterone antagonist would be indicated in a patient with heart failure with preserved ejection fraction.
Speaker(s)/Author(s)
|
Darcy Holzum, Pharm.D.
|
Activity Number
0033-0000-18-096-L01-P
Date:
11/16/18
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Location
ARB 336
Registration Closed
Registration Closed
Registration Closed
Note: This session is one of five concurrent sessions during Block 2.
Objectives
- Identify the mechanism through which prothrombin complex concentrate works to reverse VKA-associated major bleeding.
- Describe the appropriate target International Normalized Ratio (INR) goals after the administration of PCC for VKA-associated major bleed and intracranial hemorrhage.
- Determine the correct dosing strategy of four-factor prothrombin complex concentrate in the setting of VKA-associated intracranial hemorrhage.
Speaker(s)/Author(s)
|
Lauren Jacobsmeyer, Pharm.D.
|
Activity Number
0033-0000-18-095-L01-P
Date:
11/16/18
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Location
ARB 354
Registration Closed
Registration Closed
Registration Closed
Note: This session is one of five concurrent sessions during Block 2.
Objectives
- Determine a patient's CHADS2 score given their past medical history.
- Distinguish between procedures that are classified as high and low risk of bleeding.
- Recommend whether to bridge or not bridge anticoagulation for patients with atrial fibrillation given patient specific factors.
Speaker(s)/Author(s)
|
Rob Yang, Pharm.D.
|
Activity Number
0033-0000-18-090-L01-P
Date:
11/16/18
Time:
01:55 PM - 02:40 PM
CE Hours
0.75
Location
ARB 355
Registration Closed
